Keyword: Array BioPharma

A Boston University-led team found a novel activator of NRAS and developed a small molecule to inhibit the growth of NRAS-mutant melanoma.

As it tussles over licensing checks and tries to gain a reprieve, AZ quietly announced that selumetinib has once again missed the mark in a cancer test.

Merck's ERK drug had a low response rate but could be used in combinations for BRAF-mutant cancers.

Array's combo treatment nearly doubled survival in melanoma patients compared to Roche’s Zelboraf.

Array and Pfizer's initial focus is to test drug combos in a phase 1b trial in non-small cell lung cancer and pancreatic cancer.

The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to midstage assets.

Array claims $31.6 million upfront from Ono for rights to binimetinib and encorafenib in Japan and South Korea, adding to its deal with Pierre Fabre in Europe.

In our EuroBiotech roundup this week, Ipsen rejigs R&D operation, Pierre Fabre posts positive phase 3 data and Immunocore, GSK pact advances.

Array BioPharma has yanked its NDA to the U.S. regulator for its late-stage melanoma candidate binimetinib after the agency told the biotech its phase 3 Nemo data wouldn’t cut it.